Design and Development of Matrix Diffusion Control Transdermal Drug Delivery System for Antiemetic Drugs

Abstract

Administration of drugs in conventional manner is not free from toxicity and G.I. tract related problems. Also hepatic metabolism reduces bioavailability of drug and to initiate and sustained therapeutic action higher doses of drug is needed. Only I/V dreeps can solve the above problem, however continuous presence of needle in the circulatory portal is inconvenient to patient. Ultimately patient compliance is reduced, and management of disease suffers. TDDS is an answer and also a safe and convenient alternative to I/V dreeps. It obviates hepatic metabolism also, the problems concerned with G.I. tract route are absent. Processing of TDDS is also simple as compared to parentral and solid dosage forms. The present study was aimed at the development of matrix moderated transdermal drug delivery system of Ramosetron hydrochloride using various polymers. Specific strategies like use of penetration enhancers shall newlinebe employed to meet systematic requirement of drug. Different formulation variable shall be studied and optimized to achieve the desired release profile. The present research work was carried out in four parts using Ramosetron hydrochloride as a model drug, PART I formulation deals with the matrix diffusional transdermal patch by using HPMC K4M and Eudragit S100. PART II formulation deals with the matrix diffusional transdermal patch by using Ethyl Cellulose and Eudragit S100. PART III formulation deals with the matrix diffusional transdermal patch by using HPMC K4M and PVP K30. PART IV formulation deals with the matrix diffusional transdermal patch by using Ethyl Cellulose and PVP K30. Pre formulation study was performed to verify the purity of drug and also to confirm any drug: polymer interaction or change in physical state by various techniques. The melting point of Ramosetron hydrochloride complies with the reported value. FTIR study was performed for Ramosetron hydrochloride to evaluate that no chemical interaction observed between the drug and excipients used. newline